SCHEMBL23915700

SCHEMBL23915700

Nc1ncnc2c1ncn2[C@@H]1OC(COCP(=O)(O)O)[C@@H](O)[C@H]1O

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RNASEL Q05823 5/20 0.82
P2RY1 P47900 5/20 0.78
P2RY2 P41231 3/20 0.78
SRC P12931 2/20 0.78
SMN1; SMN2 Q16637 2/20 0.78
P2RY11 Q96G91 2/20 0.78
TRPM2 O94759 2/20 0.78
TAS1R3 Q7RTX0 2/20 0.78
TAS1R1 Q7RTX1 2/20 0.78
DNPH1 O43598 1/20 0.78
PRKAB2 O43741 1/20 0.78
LDHA P00338 1/20 0.78
ADRB2 P07550 1/20 0.78
FBP1 P09467 1/20 0.78
ADORA1 P30542 1/20 0.78
PRKAG1 P54619 1/20 0.78
PRKAA2 P54646 1/20 0.78
PDE4D Q08499 1/20 0.78
KCNH2 Q12809 1/20 0.78
PRKAA1 Q13131 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30395044 1.00 RNASEL (0.82) RNASELP2RY1P2RY2SRCSMN1; SMN2
SCHEMBL21839669 1.00 RNASEL (0.82) RNASELP2RY1P2RY2SRCSMN1; SMN2
SCHEMBL13033869 0.90 P2RY1 (0.75) RNASELP2RY1P2RY2SRCSMN1; SMN2
SCHEMBL9605331 0.90 P2RY1 (0.75) RNASELP2RY1P2RY2SRCSMN1; SMN2
SCHEMBL21839786 0.89 RNASEL (0.66) RNASELP2RY1P2RY2SRCSMN1; SMN2
SCHEMBL5055892 0.88 P2RY1 (0.92) RNASELP2RY1P2RY2SRCSMN1; SMN2
Adenosine Phosphate SCHEMBL20277555 0.88 P2RY1 (1.00) RNASELP2RY1P2RY2SRCSMN1; SMN2
Adenosine Phosphate SCHEMBL1338615 0.88 P2RY1 (1.00) RNASELP2RY1P2RY2SRCSMN1; SMN2
Adenosine Phosphate SCHEMBL132458 0.88 P2RY1 (1.00) RNASELP2RY1P2RY2SRCSMN1; SMN2
Adenosine Phosphate SCHEMBL19420134 0.88 P2RY1 (1.00) RNASELP2RY1P2RY2SRCSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11591355-B2 CD73 inhibitors and uses thereof PELOTON THERAPEUTICS INC. (US) 2023-02-28 US disclosed
US-20210317150-A1 CD73 INHIBITORS AND USES THEREOF PELOTON THERAPEUTICS, INC. (US) 2021-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11591355-B2 CD73 inhibitors and uses thereof ENTPD5, ENTPD1, ENTPD3 RNASEL 217/4885P2RY1 19/4885P2RY2 23/4885
US-20210317150-A1 CD73 INHIBITORS AND USES THEREOF ENTPD5, ENTPD1, NT5E RNASEL 384/4885P2RY1 28/4885P2RY2 43/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.